About FL127 FL127 is a privately held, early-stage company operating within the Flagship Pioneering ecosystem. The company is developing a first-in-category platform anchored in novel device technology, with the potential to transform how human health is
Amylyx has an audacious mission to usher in a new era for treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to
Scholar Rock is a late-stage global biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. As a global leader in
Overview: Reporting to the VP, Global Market Access, the candidate will act as the overall lead for global pricing & market access strategy for Alnylam’s Rare Disease portfolio, as well as for selected pipeline assets, bringing